Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease.

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease.

Alzheimer's disease is a neurodegenerative disorder accounting for more than 50% of cases of dementia. Diagnosis of Alzheimer's disease relies on cognitive tests and analysis of amyloid beta, protein tau, and hyperphosphorylated tau in cerebrospinal fluid. Although these markers provide re...

Full description

Bibliographic Details
Main Authors:	Payam Emami Khoonsari, Anna Häggmark, Maria Lönnberg, Maria Mikus, Lena Kilander, Lars Lannfelt, Jonas Bergquist, Martin Ingelsson, Peter Nilsson, Kim Kultima, Ganna Shevchenko
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4780771?pdf=render

Similar Items

Decreased proportion of cytomegalovirus specific CD8 T-cells but no signs of general immunosenescence in Alzheimer's disease.
by: Gabriel Westman, et al.
Published: (2013-01-01)

Alzheimer disease pathology and the cerebrospinal fluid proteome
by: Loïc Dayon, et al.
Published: (2018-07-01)

Establishing the proteome of normal human cerebrospinal fluid.
by: Steven E Schutzer, et al.
Published: (2010-06-01)

Integration of small RNAs from plasma and cerebrospinal fluid for classification of multiple sclerosis
by: Maria Needhamsen, et al.
Published: (2022-11-01)

Proteomic Analysis of Cerebrospinal Fluid in a Fulminant Case of Multiple Sclerosis
by: Jonas Bergquist, et al.
Published: (2012-06-01)

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
by: Jakob M Bader, et al.
Published: (2020-06-01)

Cognitive function in very old men does not correlate to biomarkers of Alzheimer’s disease
by: V. Velickaite, et al.
Published: (2017-09-01)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
by: Elles Konijnenberg, et al.
Published: (2020-05-01)

Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia are indistinguishable by their cerebrospinal fluid proteomes
by: Steven E. Schutzer, et al.
Published: (2023-12-01)

Proteomic differences between focal and diffuse traumatic brain injury in human brain tissue
by: Sami Abu Hamdeh, et al.
Published: (2018-05-01)

Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer’s Disease
by: Magdalena Mroczek, et al.
Published: (2022-03-01)

Identification of Candidate Biomarkers of Alzheimer’s Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics
by: Ping Liu, et al.
Published: (2023-09-01)

A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s disease
by: Lars Lannfelt
Published: (2023-11-01)

Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia
by: Yael Hirschberg, et al.
Published: (2023-12-01)

Protein fibril length in cerebrospinal fluid is increased in Alzheimer’s disease
by: Peter Niraj Nirmalraj, et al.
Published: (2023-03-01)

Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells
by: Filip Bergqvist, et al.
Published: (2019-06-01)

The cerebrospinal fluid proteome of preterm infants predicts neurodevelopmental outcome
by: Kristin Leifsdottir, et al.
Published: (2022-07-01)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
by: Johanna Nilsson, et al.
Published: (2021-01-01)

Disease phenotype prediction in multiple sclerosis
by: Stephanie Herman, et al.
Published: (2023-06-01)

Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer’s disease
by: Mari Aksnes, et al.
Published: (2021-06-01)

High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid
by: Hendrickson, R, et al.
Published: (2015)

Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimer’s Disease Patients: A Pilot Study
by: Satoshi Muraoka, et al.
Published: (2020-08-01)

Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease
by: Erica S. Modeste, et al.
Published: (2023-07-01)

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
by: Ronald C Hendrickson, et al.
Published: (2015-01-01)

Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
by: Carolina A. Magalhães, et al.
Published: (2015-12-01)

Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome.
by: Steven E Schutzer, et al.
Published: (2011-02-01)

Metabolite profiling of Alzheimer's disease cerebrospinal fluid.
by: Christian Czech, et al.
Published: (2012-01-01)

Differential proteomic profile of lumbar and ventricular cerebrospinal fluid
by: Nina Rostgaard, et al.
Published: (2023-01-01)

Quantitative Proteomics of Cerebrospinal Fluid in Paediatric Pneumococcal Meningitis
by: Guadalupe Gómez-Baena, et al.
Published: (2017-08-01)

Identification and proteomic profiling of exosomes in human cerebrospinal fluid
by: Street Jonathan M, et al.
Published: (2012-01-01)

Biochemical Differences in Cerebrospinal Fluid between Secondary Progressive and Relapsing–Remitting Multiple Sclerosis
by: Stephanie Herman, et al.
Published: (2019-01-01)

Biological Significance of the Protein Changes Occurring in the Cerebrospinal Fluid of Alzheimer’s Disease Patients: Getting Clues from Proteomic Studies
by: Cristina M. Pedrero-Prieto, et al.
Published: (2021-09-01)

Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
by: Eric B. Dammer, et al.
Published: (2022-11-01)

Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease
by: Hong Wang, et al.
Published: (2020-07-01)

POTENTIAL ALTERATION IN THE NICASTRIN LEVELS IN ALZHEIMER’S DISEASE CEREBROSPINAL FLUID
by: Luis Felipe Hernández-Villamizar, et al.
Published: (2023-10-01)

Increased inflammatory response in cytomegalovirus seropositive patients with Alzheimer's disease.
by: Gabriel Westman, et al.
Published: (2014-01-01)

Cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease
by: Jun WANG, et al.
Published: (2014-04-01)

Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease
by: Fellmann Jere, et al.
Published: (2006-05-01)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
by: Alain D. Dekker, et al.
Published: (2017-01-01)

A cerebrospinal fluid biosignature for the diagnosis of Alzheimer’s disease
by: Tatiana Barichello, et al.
Published: (2019-12-01)